With revenues declining and net losses increasing, Seattle-based Adaptive Biotechnologies on Thursday said it hired Goldman Sachs to help conduct a review of strategic alternatives for its Minimal Residual Disease… Read More
Adaptive Biotechnologies will raise up to $250 million in a deal announced Monday with healthcare investment firm OrbiMed, which will receive a cut of Adaptive’s revenue as part of the… Read More
The news: University of Washington spinout AltPep recently raised $44.4 million, according to a regulatory filing. The company declined to discuss the filing, but founder and CEO Valerie Daggett spoke… Read More
Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned. “We have made the hard decision to streamline our workforce,” a spokesperson told… Read More
Adaptive Biotechnologies, which develops technology to assess the immune response, posted $154.3 million in revenue last year, a 57% year-over-year increase. The number was revealed in the Seattle-based company’s fourth… Read More
After doubling its workforce during the pandemic, Adaptive Biotechnologies finally has room to grow. The company on Tuesday will cut the ribbon on its new 100,086 square-foot headquarters in Seattle’s… Read More
— Adaptive Biotechnologies co-founders and brothers Chad and Harlan Robins are among the directors of a new life sciences SPAC. The blank check company is called CM Life Sciences III… Read More
Seattle-based Adaptive Biotechnologies, which develops technology to sequence the human immune system to diagnose and treat disease, posted revenue of $30.2 million for the fourth quarter, up 25% from a… Read More
Adaptive Biotechnologies’ revenue fell 5% to $21 million in the second quarter, and its net loss more than doubled to $33.5 million, due in part to reduced usage of its… Read More
Topping-off ceremonies, in which workers place the last piece of structural steel for new building, have become run-of-the-mill over the past decade in Seattle’s South Lake Union neighborhood. But the… Read More
In the realm of diagnostic tests for COVID-19, there are two main approaches: PCR tests, which detect the presence of the live virus; and serology tests, which detect antibodies that… Read More
Adaptive Biotechnologies, which is working with Microsoft and Amgen to fight COVID-19 using its technology for sequencing the human immune system, reported a 65% increase in first quarter revenue, to… Read More
Microsoft and Seattle’s Adaptive Biotechnologies are seeking 1,000 people across the country for a “virtual clinical study” designed to better understand how the human immune system responds to COVID-19. Their… Read More
Pharmaceutical giant Amgen is aiming to develop a new drug to treat and prevent COVID-19, using insights from Seattle-based Adaptive Biotechnologies’ system for sequencing the human immune system, under an… Read More
Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third-quarter earnings.… Read More
Adaptive Biotechnologies‘ CEO and co-founder Chad Robins can attribute some of his company’s notable success — see its $300 million IPO in June and the $400 million previously raised —… Read More
As it closes in on one of the most valuable land deals in Seattle history, Alexandria Real Estate Equities is betting that biotech can thrive in a real estate market… Read More
Adaptive Biotechnologies is charting a massive expansion of its Seattle headquarters following the completion of a recent initial public offering. The company signed a 100,000 square-foot lease, tripling its current… Read More
Adaptive Biotechnologies had a heck of a first day as a public company. Shares of the Seattle-based biotech, which makes technology to diagnose and treat diseases by reading the immune… Read More
Follow-up: Big debut: Shares of Adaptive Biotechnologies rise 100% on first day as public company The public market is bullish on Adaptive Biotechnologies. The biotech company started trading on the… Read More
Adaptive Biotechnologies has raised the price for its initial public offering, putting itself in a position to raise more cash than any other biotech IPO this year. The Seattle-based company,… Read More
Chad Robins is a Cornell grad and Wharton School MBA who was working in real estate finance a decade ago when he was approached with a business idea by his… Read More
Adaptive Biotechnologies, a high-flying startup that makes technology to read the human immune system, has officially filed to go public and seeks to raise $230 million from investors. Founded in… Read More
As the CEO of Adaptive Biotechnologies, Chad Robins has shown a knack for turning really good ideas into a viable business. But even Robins admits that he makes for an… Read More
In the digital world, it can be easy to forget the importance of human interaction. Jill Nelson, CEO of Ruby Receptionists, and John Oppenheimer, CEO of Columbia Hospitality, believe that… Read More